Long-term study of Breyanzi for CLL/SLL in real-world care
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at people with CLL or SLL who have already been treated with the CAR T-cell therapy lisocabtagene maraleucel (Breyanzi) in routine medical care. It collects information about how well the treatment works and how patients are doing over time, without giving any new treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- You have already received treatment with lisocabtagene maraleucel (Breyanzi) in the real-world (post-marketing) setting.
- You received at least one full dose of this CAR T-cell therapy according to the approved prescribing information.
- You were not taking part in another research study at the time you got the lisocabtagene maraleucel infusion.
- You did not receive a non-standard version of the CAR T-cell product.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how health-related quality of life changes in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) when starting a new treatment. The goal is to better understand what affects well-being during therapy.
This trial tests a combination of two treatments—CAR T-cells (your own immune cells reprogrammed to attack cancer) and lenalidomide (a pill that boosts the immune system)—for people with chronic lymphocytic leukemia (CLL) that has not responded to or returned after at least one prior treatment. It aims to see if this combination is safe and works better than either alone.
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
This study looks at patients with a type of lymphoma (follicular lymphoma) who have already received a CAR T-cell therapy called liso-cel. Researchers want to track their health over time and see how well the treatment works and how safe it is in routine medical care.
This study looks at patients with mantle cell lymphoma who have already received a treatment called lisocabtagene maraleucel (Liso-cel) as part of standard care. It helps researchers understand how well the therapy works in real-world use.
This study tests a combination of two treatments: a targeted pill (nemtabrutinib) and a special immune cell therapy (lisocabtagene maraleucel, or liso-cel) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or has not responded to previous treatment. The goal is to see if giving the pill first helps the cell therapy work better.
Hear when a new Chronic Lymphocytic Leukemia (CLL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.